Viromed Medical AG Advances Cold Plasma Research for Lung Health

Viromed Medical AG is advancing research on cold plasma as a potential "digital antibiotic" for preventing ventilator-associated pneumonia (VAP). Led by Prof. Dr. Hortense Slevogt of the BREATH research network, the study explores the safety and effectiveness of cold plasma in killing respiratory bacteria. This innovation aims to curb VAP fatalities in Germany, where the condition affects 23-36% of ventilated patients and has a mortality rate of 10-13%.

Cold plasma shows promise due to its quick action against antibiotic-resistant bacteria, unlike traditional antibiotics. CEO Uwe Perbandt emphasized its ability to destroy germs without risking resistance, labeling cold plasma a major forward step in combating infection-related deaths. With positive preliminary study results, cold plasma could transform the treatment of ventilated patients, alleviating healthcare burdens and antibiotic dependence.